ArticleFrontiers in medicine2026
Gradient elevation of serum CYFRA21-1 and its synergy with KL-6 for risk stratification in rheumatoid arthritis-associated interstitial lung disease.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to assess the clinical value of cytokeratin 19 fragment (CYFRA21-1) and its correlation with Krebs von den Lungen-6 (KL-6) in stratifying the severity of rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Methods: Data were retrospectively collected from 178 patients with rheumatoid arthritis (RA) admitted to our hospital between November 2024 and September 2025. The classification of patients into subgroups was based on chest high-resolution computed tomography (HRCT) findings, with 82 without interstitial lung disease (ILD), 53 with mild ILD, and 43 with advanced ILD. Serum KL-6 levels were measured using a latex agglutination assay, and the levels of tumor markers were determined by chemiluminescent immunoassay. Results: Serum CYFRA21-1 levels were significantly higher in both the RA-mild ILD and RA-advanced ILD groups compared with the RA-no ILD group (2.10 ng/mL vs. 1.90 ng/mL, Conclusion: CYFRA21-1 exhibited graded expression and a positive correlation with KL-6, serving as a valuable serum biomarker for risk stratification and severity assessment in RA-ILD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.